CAS
DFTX

Coppell Advisory Solutions’s Definium Therapeutics DFTX Stock Holding History

Coppell Advisory Solutions’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$354K Buy
+1
New +$25 0.03% 352
2025
Q1 		– Sell
-1
Closed -$7 – 1262
2024
Q4 		$7 Hold
1
– – ﹤0.01% 1970
2024
Q3 		$6 Hold
1
– – ﹤0.01% 1872
2024
Q2 		$7 Buy
+1
New +$9 ﹤0.01% 1793
2023
Q4 		$4 Buy
+1
New +$3 ﹤0.01% 1718

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Coppell Advisory Solutions's DFTX Position: Q2 2026 in Review

Coppell Advisory Solutions opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 1 share worth $354K. The stake represents 0.03% of the portfolio and ranks #352 among its holdings. This is a return to the name: Coppell Advisory Solutions previously reported a position in DFTX as recently as Q4 2024.

Coppell Advisory Solutions first reported a position in DFTX in Q4 2023 and has held it in 5 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Coppell Advisory Solutions held 1 share of Definium Therapeutics worth $354K as of Q2 2026.
  • Definium Therapeutics was a new Coppell Advisory Solutions position in Q2 2026.
  • Definium Therapeutics made up 0.03% of Coppell Advisory Solutions's portfolio in Q2 2026, its #352 holding.
  • Coppell Advisory Solutions first reported a position in Definium Therapeutics in Q4 2023 and has held it in 5 quarters since.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Coppell Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.